NASDAQ:DTIL

Precision Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy DTIL

*Your capital is at risk

$6.04

-0.280 (-4.43%)

At Close: Jun 03, 2026

Precision BioSciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 12.42. In total, the insiders bought 1.65M and sold 142.66K DTIL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	12.42
● Buy	1.65M shares
● Sell	142.66K shares
87% Buy Activity Weak Positive Correlation
Buy Signal Medium Confidence May 20, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (87% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 16, 2025 Buy	Common Stock P-Purchase	Frankel Stanley Director	Director	2 700 Value: $12.7K
Dec 16, 2025 Buy	Common Stock P-Purchase	Germano Geno J Director	Director	3 000 Value: $14.2K
Dec 15, 2025 Buy	Common Stock P-Purchase	Brown Melinda Director	Director	1 381 Value: $7K
Nov 03, 2025 Sell	Common Stock S-Sale	Amoroso Michael President And CEO	CEO / President	3 409 Value: $22.1K
Nov 03, 2025 Sell	Common Stock S-Sale	Scimeca Dario General Counsel And Secretary	Officer	665 Value: $4K
Nov 03, 2025 Sell	Common Stock S-Sale	Kelly John Alexander Chief Financial Officer	C-Suite Officer	1 303 Value: $8K
Nov 03, 2025 Buy	Restricted Stock Units M-Exempt	Amoroso Michael President And CEO	CEO / President	9 444 Value: $69.5K
Nov 02, 2025 Buy	Common Stock M-Exempt	Amoroso Michael President And CEO	CEO / President	9 444 Value: $57.0K
Nov 02, 2025 Buy	Restricted Stock Units M-Exempt	Scimeca Dario General Counsel And Secretary	Officer	1 835 Value: $11.1K
Nov 02, 2025 Buy	Restricted Stock Units M-Exempt	Kelly John Alexander Chief Financial Officer	C-Suite Officer	3 605 Value: $21.8K
Nov 02, 2025 Buy	Common Stock M-Exempt	Scimeca Dario General Counsel And Secretary	Officer	1 835 Value: $11.1K
Nov 02, 2025 Buy	Common Stock M-Exempt	Kelly John Alexander Chief Financial Officer	C-Suite Officer	3 605 Value: $21.8K
Sep 26, 2025 Buy	Common Stock P-Purchase	Frankel Stanley Director	Director	2 700 Value: $13.4K
Sep 26, 2025 Buy	Common Stock P-Purchase	Frankel Stanley Director	Director	2 700 Value: $13.4K
Sep 22, 2025 Buy	Common Stock P-Purchase	Brown Melinda Director	Director	1 400 Value: $7K
Sep 22, 2025 Buy	Common Stock P-Purchase	Brown Melinda Director	Director	1 400 Value: $7K
Jul 03, 2025 Sell	Common Stock S-Sale	Kelly John Alexander Chief Financial Officer	C-Suite Officer	14 827 Value: $63.2K
Jul 03, 2025 Sell	Common Stock S-Sale	Kelly John Alexander Chief Financial Officer	C-Suite Officer	14 827 Value: $63.2K
Jun 25, 2025 Buy	Common Stock P-Purchase	Brown Melinda Director	Director	1 682 Value: $7K
Jun 25, 2025 Buy	Common Stock P-Purchase	Buehler Kevin Director	Director	5 076 Value: $21.1K
Jun 25, 2025 Buy	Common Stock P-Purchase	Buehler Kevin Director	Director	5 076 Value: $21.1K
Jun 25, 2025 Buy	Common Stock P-Purchase	Brown Melinda Director	Director	1 682 Value: $7K
Jun 03, 2025 Buy	Restricted Stock Units A-Award	Germano Geno J Director	Director	21 000 Value: $108.2K
Jun 03, 2025 Buy	Restricted Stock Units A-Award	Pire Shari Lisa Director	Director	21 000 Value: $108.2K
Jun 03, 2025 Buy	Restricted Stock Units A-Award	Frankel Stanley Director	Director	21 000 Value: $108.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PRECISION BIOSCIENCES INC.

Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetica...

Read Full Profile Here